Entities / Company
BioArctic.
Swedish pharmaceutical company
- Reports this week
- 0
- Active events
- 0
- Connections
- 10
What's happening
Reports per dayLast 90 days
90 days agoDrag either end to show only events that began in that periodToday
One to three months ago
-
BioArctic and Eli Lilly and Company are collaborating on potential treatments for neurodegenerative diseases.Some support3 reports
-
BioArctic and Mesenkia Therapeutics have initiated a research collaboration to explore novel glioblastoma treatment options.Some support1 report
-
BioArctic and Eisai partnered to present clinical evidence regarding lecanemab.Some support3 reports1 development inside
-
BioArctic and Eisai developed the drug Leqembi.Some support1 report
-
Biogen, Eisai, and BioArctic announced the joint commercialization of lecanemab for Alzheimer's treatment.Well supported3 reports1 development inside
Gone quiet
No new reports in 90+ daysNo events began in the chosen period. Widen it, or reset.
Around BioArctic this week
News at the entities that move BioArctic most-
Eisai StructuralEisai presented research at the European Society for Medical Oncology (ESMO) Congress.Moves BioArctic
-
FDA StructuralNeurogene Inc. developed a gene therapy for Rett syndrome and received FDA agreement for a registrational trial design.Moves BioArctic
-
Biogen StructuralApellis is acquired by Biogen, and Aspaveli receives approval in the European Union.Moves BioArctic
-
Eli Lilly and Company OperationalMedicare coverage is driving growth in the obesity drug market, leading to raised price targets for Eli Lilly.Moves BioArctic
-
London Shared contextProtests occurred outside the Department for Energy Security and Net Zero in London, coinciding with reports of fear in Portugal.Moves BioArctic
Connections
The 6 strongest of 10, analyzed from the reporting. The bars show how strongly a change on one side reaches the other.-
Eisai Structural
BioArctic and Eisai are in a strategic research alliance for the co-development and commercialization of Leqembi, with BioArctic receiving royalties.
-
FDA Structural
BioArctic's drug development and commercialization are formally dependent on regulatory designation and approval from the FDA.
-
Biogen Structural
A successful technology transfer led to a current, ongoing joint venture requiring shared financial reporting.
-
Lars Lannfelt Structural
BioArctic's antibody development and innovation are founded upon research findings by Lars Lannfelt.
-
Eli Lilly and Company Operational
The companies are engaged in research collaboration regarding potential treatments for neurodegenerative diseases.
-
London Shared context
BioArctic presented a study at a conference held in London.
History
Events by the month they beganAugust 2026
2 eventsJune 2026
4 events- BioArctic and Eli Lilly and Company are collaborating on potential treatments for neurodegenerative diseases.
- BioArctic and Eisai partnered to present clinical evidence regarding lecanemab.
- Biogen, Eisai, and BioArctic announced the joint commercialization of lecanemab for Alzheimer's treatment.
- The pharmaceutical industry is seeing developments in ALS drug treatment, including partnerships and drug approvals involving major companies.